City of Hope
In presentations at AACR, researchers discussed how drug sensitivity and other functional testing is improving precision oncology amid systemic barriers.
Texas Research Institute, TGen, OncoHost Partner to ID Lung Cancer Resistance Mechanisms
Collaborators will study the immune profiles and molecular features of NSCLC to better understand patterns of response and resistance to immunotherapy.
Leukemia Patients See Survival Benefit With Integrated Functional Drug, Molecular Testing Approach
Premium
Data presented at ASH's annual meeting showed that patients on matched drugs based on genomic sequencing and high-throughput drug testing lived longer than those who did not.
Eureka, City of Hope Begin Phase I/II Trial of T-Cell Therapy in GPC3-Positive Liver Cancer
The partners will enroll 12 patients with GPC3-positive tumors who have failed or not tolerated at least two prior systemic agents.
City of Hope, Imugene Begin Trial of Oncolytic Virus in Advanced Solid Cancers
The partners will see if the oncolytic virus CF33-hNIS, dubbed Vaxinia, can increase PD-L1 tumor expression and make patients responsive to Merck's Keytruda.